持续发展，向下一个百年迈进
本公司由五大部门构成，以开发为社会贡献的产品为目标。
IR信息
FY2025 Financial Results Presentation Materials with Script
Notice Concerning Recording of Extraordinary Income and Losses (Consolidated and Non-consolidated)
Results Presentation of FY2025
FY2025 Summary of Consolidated Financial Statements
产品信息
Price Revision for Denka Chloroprene
Notice Regarding Results of Tender Offer for Share Certificates, Etc. of KAINOS Laboratories, Inc. (Securities Code: 4556)
Announcement of Extraordinary Gains (Gain on Sale of Investment Securities)
